Android app Apple app link

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

By Yahoo! Finance   |   5 days ago
RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

New anti-cancer therapies like RYBREVANT show promise in treating lung cancer with EGFR mutations, improving patient outcomes. The approval offers hope and improved quality of life, addressing significant treatment gaps.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.